Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...
The SPDR S&P Biotech ETF (NYSEARCA:XBI) is on pace for its best trading week in 21 months as the exchange traded fund earlier this week hit a 23-month trading low. XBI is now +8.2% and +2.6% for the day. The biotech fund had not seen such bullish weekly moves since Jun...
The shares of commercial-stage biotech, BioCryst Pharmaceuticals (NASDAQ:BCRX) are trading lower Thursday after its Chief Discovery Officer Babu Yarlagadda disclosed the sale of 20,000 company shares. The transaction marks the first insider selling at BioCryst (excluding option exercises) sin...
The outlook for the pharmaceutical and biotech industry is good thanks to resilience versus crises and large macro tailwinds. XBI and many biotech names have sold off a lot over the last year. The ETF is now trading lower than before the pandemic. XBI's approach is different from ...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: BioCryst Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
On Thursday, BioCryst Pharmaceuticals (NASDAQ:BCRX) highlighted the long-term potential of its oral hereditary angioedema (HAE) therapy Orladeyo after the release of latest data from its APeX-2 trial designed to evaluate the once-daily drug as a prophylactic treatment. 96-week data of the 121...
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatme...
BioCryst Pharmaceuticals (NASDAQ: BCRX) attracted the wrong kind of attention Wednesday with its latest quarterly results. By the end of the trading session, the stock had fallen by nearly 6%. For the fourth quarter, BioCryst brought in net revenue of $47.2 million, nearly 12 ti...
Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q4 2021 Earnings Call Feb 23, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q4 2021 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...